LEADER 04669nam 2201153z- 450 001 9910557345403321 005 20231214133635.0 035 $a(CKB)5400000000042436 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76632 035 $a(EXLCZ)995400000000042436 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRadiation Response Biomarkers for Individualised Cancer Treatments 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (231 p.) 311 $a3-0365-1684-0 311 $a3-0365-1683-2 330 $aPersonalised medicine is the next step in healthcare, especially when applied to genetically diverse diseases such as cancers. Naturally, a host of methods need to evolve alongside this, in order to allow the practice and implementation of individual treatment regimens. One of the major tasks for the development of personalised treatment of cancer is the identification and validation of a comprehensive, robust, and reliable panel of biomarkers that guide the clinicians to provide the best treatment to patients. This is indeed important with regards to radiotherapy; not only do biomarkers allow for the assessment of treatability, tumour response, and the radiosensitivity of healthy tissue of the treated patient. Furthermore, biomarkers should allow for the evaluation of the risks of developing adverse late effects as a result of radiotherapy such as second cancers and non-cancer effects, for example cardiovascular injury and cataract formation. Knowledge of all of these factors would allow for the development of a tailored radiation therapy regime. This Special Issue of the Journal of Personalised Medicine covers the topic of Radiation Response Biomarkers in the context of individualised cancer treatments, and offers an insight into some of the further evolution of radiation response biomarkers, their usefulness in guiding clinicians, and their application in radiation therapy. 606 $aMedicine$2bicssc 610 $acarbon-ion radiotherapy 610 $ahead-and-neck tumors 610 $asquamous cell carcinoma 610 $aradiosensitivity 610 $arelative biological effectiveness 610 $alung cancer 610 $aradiotherapy 610 $aradiotherapy monitoring 610 $aradiation-induced lung injury 610 $aRILI 610 $apneumonitis 610 $aradiation-induced lung fibrosis 610 $aRILF 610 $acirculating biomarkers 610 $amicroRNA 610 $amicronuclei 610 $auterine cervical cancer 610 $acGAS 610 $aSTING 610 $aabscopal effect 610 $aimmunotherapy 610 $aPBMCS 610 $amicronucleus assay 610 $abiological dosimetry 610 $ahuman blood 610 $agenotoxicity tests 610 $aionizing radiation 610 $abiomarkers 610 $adicentric assay 610 $agamma H2AX foci assay 610 $ahealth surveillance analyses 610 $aclonogenic assays 610 $amethods 610 $aplating 610 $acancer 610 $aradiation 610 $ahead and neck cancer 610 $aexosomes 610 $aserum 610 $ametabolomics 610 $aGC/MS 610 $abiodosimetry 610 $achromosome aberrations 610 $anormal tissue toxicity 610 $apredictive tests 610 $anormal tissue 610 $abiomarker 610 $aprotein 610 $aimmune infiltrate 610 $astroma 610 $atumour microenvironment 610 $aproteomics 610 $atelomeres 610 $achromosomal instability 610 $ainversions 610 $aprostate cancer 610 $aIMRT 610 $amachine learning 610 $aindividual radiosensitivity 610 $alate effects 610 $apersonalized medicine 610 $aliquid biopsy 610 $acirculating tumour cells 610 $aextracellular vesicles 610 $amicroRNAs 610 $aimmune system 610 $ainflammation 615 7$aMedicine 700 $aBadie$b Christophe$4edt$01303371 702 $aRutten$b Eric Andreas$4edt 702 $aBadie$b Christophe$4oth 702 $aRutten$b Eric Andreas$4oth 906 $aBOOK 912 $a9910557345403321 996 $aRadiation Response Biomarkers for Individualised Cancer Treatments$93026959 997 $aUNINA